<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) has been shown to play an important role in the pathophysiology of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, its contribution to the pathogenesis of experimentally induced <z:hpo ids='HP_0001727'>thromboembolic stroke</z:hpo> is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we pharmacologically manipulated NO levels in the <z:hpo ids='HP_0011009'>acute</z:hpo> post-thrombotic stage and determined the effects on behavior and histopathology </plain></SENT>
<SENT sid="2" pm="."><plain>The following drugs were used: <z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi>-<z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>), a non-specific endothelial and neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (eNOS and nNOS) inhibitor, 3-<z:chebi fb="1" ids="22927,47265">bromo</z:chebi>-7-nitroindazole (7-NI), a specific inhibitor for nNOS, the NO precursor, exogenous <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> and the NO-donor, 3-morpholino-sydnonimine (SIN-1) </plain></SENT>
<SENT sid="3" pm="."><plain>Male Wistar rats (n = 76) were randomly assigned to receive vehicle or drug immediately after common carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> (CCAT) </plain></SENT>
<SENT sid="4" pm="."><plain>Regional measurements of cortical NOS activity using the [3H]<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> to [3H]<z:chebi fb="0" ids="16349">L-citrulline</z:chebi> conversion assay were decreased 1 h after treatment with L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> and 7-NI by 50 and 65%, respectively; hippocampal NOS activity was reduced with L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> by 35% and with 7-NI by 65% </plain></SENT>
<SENT sid="5" pm="."><plain>L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> significantly worsened forelimb placing as compared to other groups </plain></SENT>
<SENT sid="6" pm="."><plain>7-NI accelerated sensorimotor recovery </plain></SENT>
<SENT sid="7" pm="."><plain>Water maze retention deficits were noted 48 h after CCAT and these were exacerbated by L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Histopathological protection was conferred in the hippocampus by 7-NI and SIN-1; conversely, L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> increased neuronal injury in the contralateral cortex </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> had no effect on these outcomes </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, both structural and functional consequences of CCAT can be aggravated by limiting endothelial NO production in the acutely post-thrombotic brain </plain></SENT>
<SENT sid="11" pm="."><plain>In contrast, inhibition of nNOS and infusion of an NO donor has a beneficial effect on pathology </plain></SENT>
</text></document>